Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia

Erica W. Mandell, Panagiotis Kratimenos, Steven H. Abman, Robin H Steinhorn

Research output: Contribution to journalReview article

Abstract

Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and postdischarge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.

Original languageEnglish (US)
JournalClinics in Perinatology
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Bronchopulmonary Dysplasia
Pharmaceutical Preparations
Premature Birth
Phenotype
Lung
Therapeutics

Keywords

  • Bronchopulmonary dysplasia
  • Chronic pulmonary insufficiency of prematurity
  • Lungs
  • Pharmacology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia. / Mandell, Erica W.; Kratimenos, Panagiotis; Abman, Steven H.; Steinhorn, Robin H.

In: Clinics in Perinatology, 01.01.2019.

Research output: Contribution to journalReview article

Mandell, Erica W. ; Kratimenos, Panagiotis ; Abman, Steven H. ; Steinhorn, Robin H. / Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia. In: Clinics in Perinatology. 2019.
@article{cf8ed59bbb17451b80b83ee7794b8320,
title = "Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia",
abstract = "Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and postdischarge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.",
keywords = "Bronchopulmonary dysplasia, Chronic pulmonary insufficiency of prematurity, Lungs, Pharmacology",
author = "Mandell, {Erica W.} and Panagiotis Kratimenos and Abman, {Steven H.} and Steinhorn, {Robin H}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clp.2019.02.011",
language = "English (US)",
journal = "Clinics in Perinatology",
issn = "0095-5108",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia

AU - Mandell, Erica W.

AU - Kratimenos, Panagiotis

AU - Abman, Steven H.

AU - Steinhorn, Robin H

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and postdischarge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.

AB - Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and postdischarge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.

KW - Bronchopulmonary dysplasia

KW - Chronic pulmonary insufficiency of prematurity

KW - Lungs

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85063455030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063455030&partnerID=8YFLogxK

U2 - 10.1016/j.clp.2019.02.011

DO - 10.1016/j.clp.2019.02.011

M3 - Review article

C2 - 31010561

AN - SCOPUS:85063455030

JO - Clinics in Perinatology

JF - Clinics in Perinatology

SN - 0095-5108

ER -